Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH), in Respiratory Medicine, January 2023

This Phase 1 study evaluated efficacy/safety of inhaled single-dose MK-5475, an investigational, small-molecule stimulator of soluble guanylate cyclase designed for inhaled delivery via a dry-powder inhaler device, in participants with pulmonary arterial hypertension. The findings reveal that treatment with inhaled single-dose MK-5475 reduced pulmonary vascular resistance and increased pulmonary blood volume. Compared to the placebo, MK-5475 was […]

Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH), in Respiratory Medicine, January 2023 Read Post »

Gossamer Bio announces seralutinib meets primary endpoint in phase 2 TORREY study in pulmonary arterial hypertension, December 6, 2022

On December 6, 2022, Gossamer Bio, Inc. announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension. Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension. Read more about the TORREY

Gossamer Bio announces seralutinib meets primary endpoint in phase 2 TORREY study in pulmonary arterial hypertension, December 6, 2022 Read Post »

Want to find out more about sotatercept, a potential new pulmonary arterial hypertension treatment? Check out this interview with Dr. Mark Tushner, care of the Pulmonary Hypertension Association UK (PHA UK), November 2022

the Pulmonary Hypertension Association UK (PHA UK) has recently posted a very informative interview with Dr Mark Toshner, pulmonary hypertension Specialist and Associate Professor, about sotatercept, a promising new pulmonary arterial hypertension drug (results for the STELLAR study were announced recently) which is the first to target the root cause of the disease. The video

Want to find out more about sotatercept, a potential new pulmonary arterial hypertension treatment? Check out this interview with Dr. Mark Tushner, care of the Pulmonary Hypertension Association UK (PHA UK), November 2022 Read Post »

“Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study”, The Lancet, October 2022

RACE is a (completed) phase 3, multicentre, open-label, parallel-group, randomised controlled trial done in 23 French centres of expertise for pulmonary hypertension enrolling treatment-naive patients aged 18–80 years with newly diagnosed, inoperable chronic thromboembolic pulmonary hypertension and pulmonary vascular resistance of more than 320 dyn·s/cm5. A summary of the article is available on The Lancet

“Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study”, The Lancet, October 2022 Read Post »

TRANSLATE »
Scroll to Top